Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment
复制标题
DOI：
10.1182/blood-2003-05-1721
复制
发表时间：
2004-03-01
期刊：
影响因子：
20.3
通讯作者：
Wald, A
中科院分区：
文献类型：
--
作者：
Casper, C;Nichols, WG;Wald, A
多中心Castleman病（MCD）是一种与人类免疫缺陷病毒（HIV）感染者中人类疱疹病毒8 （HHV-8）感染相关的淋巴细胞增生性疾病。治疗通常包括化疗，并经常发生进展为非霍奇金淋巴瘤。MCD的部分特征是活跃的HHV-8复制，MCD的许多症状可能归因于病毒基因产物。我们在一系列的3例病例报告中描述了更昔洛韦对MCD临床和病毒学过程的影响。两名患者接受静脉或口服更昔洛韦治疗后，MCD发作性发作和可检测到的HHV-8 DNA的频率降低，而第三名患者接受静脉更昔洛韦治疗后，急性肾和呼吸衰竭发作后恢复。这些数据为抗HHV-8抗病毒药物在MCD治疗中的效用提供了体内证据。(C) 2004年由美国血液病学会出版。
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection among persons with human immunodeficiency virus (HIV) infection. Treatment often includes chemotherapy, and progression to non-Hodgkin lymphoma frequently occurs. MCD is characterized in part by active HHV-8 replication, and many of the symptoms of MCD may be attributable to viral gene products. We describe the effect of ganciclovir on the clinical and virologic course of MCD in a series of 3 case reports. Two patients experienced a reduction in the frequency of episodic flares of MCD and detectable HHV-8 DNA with intravenous or oral ganciclovir, whereas the third patient recovered from an acute episode of renal and respiratory failure with intravenous ganciclovir therapy. These data provide in vivo evidence for the utility of antiviral agents against HHV-8 in the management of MCD. (C) 2004 by The American Society of Hematology.